| PDF - Published Version (1MB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-430633
- DOI to cite this document:
- 10.5283/epub.43063
Abstract
Background: Linezolid is used for the treatment of soft tissue infections in critically ill patients. However, data for characterizing the pharmacokinetics (PK) and assessing whether effective concentrations are reached at the target site are lacking. We hypothesized that current dosing regimens do not lead to effective concentrations in the plasma and interstitial fluid (ISF) of subcutaneous ...

Owner only: item control page